{"id":"W2991627091","doi":"10.1016/j.jtho.2019.11.004","title":"Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Berlin Mathematical School; Exelixis; Meso Scale Diagnostics; Takeda Pharmaceutical Company; AbbVie; Gilead Sciences; Takeda Oncology; University of Colorado; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Novartis; GlaxoSmithKline; Sanofi-Aventis Deutschland; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Refractory (planetary science); Oncology; Internal medicine; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002730508,0.0006713243,0.00103379,0.0002382355,0.0002800569,0.001054015,0.0003872071,0.0005945454,0.001901449],"category_scores_gemma":[0.00173622,0.0002192756,0.001219976,0.0003898721,0.0002639581,0.0005527965,0.0003010954,0.001247234,0.0003553932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005275045,"about_ca_system_score_gemma":0.0006536657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007418738,"about_ca_topic_score_gemma":0.00224687,"domain_scores_codex":[0.9993624,0.0003568016,0.00004547607,0.00009415684,0.000072343,0.00006881399],"domain_scores_gemma":[0.9988716,0.0002115874,0.0005467013,0.00008284805,0.00007390003,0.0002132936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8122849,0.003266221,0.06717806,0.001470889,0.008904657,0.0003123986,0.0001681482,0.002033946,0.009650708,0.0001817025,0.006719444,0.08782887],"study_design_scores_gemma":[0.461401,0.1176947,0.3873479,0.0004070552,0.01425354,0.001057403,0.0001498639,0.002760224,0.00397205,0.0006062158,0.01022758,0.0001224414],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823384,0.01247684,0.0002151092,0.0005214214,0.00009265674,0.0002744824,0.002219719,0.00005610352,0.001805271],"genre_scores_gemma":[0.9908459,0.002981028,0.0003141073,0.0004175967,0.00016524,0.0003101655,0.004072502,0.00001182021,0.0008816635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002730508,"threshold_uncertainty_score":0.01444048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02598260838158858,"score_gpt":0.4525316280524112,"score_spread":0.4265490196708226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}